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Abstract
Homocystinuria is a metabolic disorder associated with defects in genes encoding for methionine metabolism enzymes. Vascular and
connective tissue manifestations such as deep venous thrombosis, ectopia lentis and skeletal alterations are the major clinical features.
We investigated the clinical manifestations of 5 Italian homocystinuric patients, performed mutation screening analysis on cystationine
beta-synthase (CBS) gene and searched for genotype/phenotype correlations.
We detected mild cardiovascular and skin connective tissue stigmas in these patients, never reported in homocystinuric patients before.
We found 1 novel and 7 known mutations. Our patients carried no other mutation associated with venous thrombosis. Our data stress the
importance of extending the clinical investigation for connective tissue manifestations in homocystinuric patients to all the organs/systems
involved in Marfan syndrome, also suggesting long term follow-ups for cardiovascular manifestations.
© 2008 Elsevier Ireland Ltd. All rights reserved.
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Homocystinuria (MIM# 236200) is a rare metabolic dis-
order (1:344.000) mainly due to cystathione beta-synthase
(CBS) deficiency which causes increased urinary homo-
cysteine (Hcy) and methionine excretion [1]. Major clinical
manifestations involve eyes, skeleton, central nervous and
vascular systems. Ocular and skeletal manifestations are
shared by both homocystinuria and Marfan syndrome (MFS)
patients, while aortic dilatation and valve prolapse and re-
gurgitation, have been reported only in Marfan patients.
Patients are diagnosed during infancy, mostly after the
onset of ectopia lentis (EL) [1,2], or because of venous throm-
bosis in later age. The homotetramer CBS (EC 4.2.1.22;
chr.21q22.3) (Fig. 1), enzyme in the transulfuration pathway,
converts the potentially toxic Hcy into cysteine [3]. A
continuously updated CBS website (http://www.uchsc.edu/
sm/cbs/cbs data/cbsmain.htm) lists 140 mutations in 624
patient alleles [4]. Homocystinuria can also be due to muta-
tions in 5–10, Methylenetetrahydrofolate reductase (MTHFR;
MIM#236250)[5], methionine synthase reductase (MTRR)
[6] and methionine synthase (MTR)[7] genes.
We investigated 5 homocystinuric Italian patients and
an echocardiographic study/examination was performed
according to the guidelines of the American Society of
Echocardiography [8]. Controls were selected among appar-
ently healthy Italian subjects with no history of sudden death,
without venous thrombosis, cardiovascular, skeletal or eyes
Marfan or homocystinuric manifestations. Biochemical and
genetic factors predisposing to thrombotic events were eval-
uated as previously reported [9–12]. Genomic DNA muta-
tion analysis of CBS gene (Table 1) was performed [13].
Clinical characteristics and molecular data of the 5 pa-
tients (4 males and 1 female) are shown in Table 2. In 3 cases
(Pts #1,3,4) the diagnosis was made after the first thrombotic
event, in the other 2 cases (Pts#1,5) upon detection of EL.
All values for biochemical and genetic factors turned out to
be in a normal range except for the following: two individuals
who were homozygous for MTHFR: c.677CNT(Pt#3) and
c.1298ANG(Pt#1); 2 were heterozygous for:MTRc.2756ANG
(Pt#5) and MTHFRc.1298ANG(Pt#4); only one was double
heterozygote for MTRc.2756ANG and MTHFRc.677CNT
(Pt#2).
We found 6 heterozygous missense mutations (p.Pro49-
Leu, p.Arg125Gln, p.Ile278Thr, p.Ala157Pro, p.Gly307Ser,
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p.Arg336His); 1 in frame deletion (p.Ile429del), 1 mRNA
splicing mutation that alters intron 12 splice donor site
(c.1357+1GNA).
Patient #2 leads the novel c.469GNC nucleotide CBS
substitution in exon 4 corresponding to the p.Ala157Pro
change localized in a highly conserved region (catalytic
domain) at the dimer interface of the tetrameric protein
structure. We found c.469GNC mutation in 3 out of 300
controls, so by definition this mutation has to be considered
as a polymorphism. Moreover, this substitution would in-
duce a bend in the protein structure but its pathogenic role
remains to be defined for the relatively high frequency in
controls (1%).Alternatively, a second mutation could be
present in the promoter region not investigated.
Patient #3 leads another mutation, carried by an Argentinean
patient [14], recently published on-line that consists in a deletion
of three nucleotides (c.1286_1288delTCA) causing a deletion of
amino acid Ile429, the mutation being positioned in a non
conserved domain. This mutation, however, is not present in 50
South American [14] and 300 Italian controls (this report).
The other 6 mutations are already reported in the database
as pathogenic mutations.
The parents of patient #5 underwent hcy dosage and CBS
mutation analysis. The father carried mutation p.Ile278Thr
and mildly increased hcy level (23 µmol/L; n.v.b19) while
the mother, presenting mutation p.Arg125Gln, had normal
hcy levels (9.8 µmol/L; n.v.b13), both in heterozygous state.
Eight polymorphisms, 5 novel and 3 already published in
the CBS database, were found (Table 2).
In our patients we detected heart and skin manifestations
never reported in homocystinuric patients such as mild heart
valve prolapse and/or regurgitation, and striae distensae
suggesting, for the first time, that these patients can develop
cardiovascular manifestations.
MacLean et al. [15] suggested that clinical homocysti-
nuric manifestations related to the connective tissue may be
correlated to the decrease of CBS production causing both
an increase of hcy levels and a decrease of cysteines. The
decrease of cysteines may affect the qualitative and quan-
titative synthesis of connective tissue proteins causing EL
and other connective tissue manifestations. This hypothesis is
Fig. 1. The protein domains of human CBS. In the upper side are the binding sites for Heme, pyridoxal 5'-phosphate (PLP) and S-adenosyl-L-methionine
(AdoMet). In the lower side the mutations described in this paper together with the identification number of patients are reported.(BD: Binding Domain; CD:
Catalytic Domain).
Table 1
Primers used for mutation screening analysis of the human cbs gene.
Exon name Sequence (5'→3') Size
(bp)
Annealing
temperature
[°C]
Number
of
cycles
1 1S ggAACCCCACAgCATCCgA 311 62 40
1AS ggTTATggATCAgCCCTCTT
2 2S TgTCTgCCAgggCTggTAC 272 60 35
2AS CCTTgCCTAAgggATCCATC
3 3S AAgCCCgTCCCCCACCCT 338 64 35
3AS ATgCggCTgCAgCTCAgC
4+5 4S AACCggCATCggggTgTgC 450 64 35
5AS CCgAgACCCTCCTAgggAAT
6 6S CACCTggggCCTggAgAC 232 66 35
6AS TACACTCCCAggCAgCCAg
7 7S gCAACgAgggCTgCTCCAA 309 62 40
7AS ACAgCTTTCAgCTCAgAAgC
8 8S AggCAgTTgTTAACggCggT 319 62 40
8AS TTggggCCCAgggTCAgC
9 9S TCTggggTCCTACCgCCTA 291 62 40
9AS TgCAggTCggTggCTgACT
10 10S gACATgCTCCCATgCgTgC 279 62 40
10AS Kruger at al 2003
11 11S AgCACTTgggggTCTCTgC 298 62 35
11AS AgggCCAgCACAggCCAC
12 12S ggTCCCTgTggCCTCCTg 297 64 40
12AS gTgACACTgACGgggTggA
13 13S CAgAgAgCgCTCCTCCCTg 267 66/64/62 3/3/32
13AS CCTgTTTgAgCTgCCTgTAgg
14 14S TCCCACgTTCggCTgCCAC 280 64 40
14AS CATggCAgAggCCAggCTT
15 15S gAgTTgggAggggCCCTg 258 62 35
15AS AggACCCTggAAggCCTC
16 16S CgCAgCAgCCCACCCAgC 236 62 40
16AS TAgggCTCAggAAAgCgAAG
17 17S gTCTCCCCTCgTTAACACAT 281 64 40
17AS CAAACTgCTCCCgCCAgC
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Table 2
Clinical data, heterozygous CBS mutations, polymorphisms of CBS and other genes implicated in the hcy metabolism found in 5 homocystinuric patients.
Clinical manifestations
ID° Age of
presentation
(EL or venous
thrombosis)/age
of diagnosis
Sex/
age
Vascular
involvement
Cardiac involvement Eye
involvement
Skeletal
involvement
Other
features
tHcy μmol/L Location of Mutations and polymorphisms in CBS
and in other metabolism hcy genes (exon, Nucleotide
change, Aminoacid Change, type of mutation)
1 15/30 M/30 DVT No involvement –Ectopia lentis –Kyphoscoliosis Striae 193.6 Exon9, c.9852GNA, p.Arg336His, Missense
Exon6, c.6955CNT (0.65/0.35),p.Tyr233Tyr, SNP
IVS11, c.1224+141GNA Novel IVS12, c.1358-55CNT Novel
IVS12, c.1358-30CNT (0.76/0.24) SNP
IVS13, c.1467+32ANG Novel
MTHFR c.1298aNG (GG)
–Myopia –Pectus
excavatum
2 16/16 M/21 No involvement –Mitral valve prolapse
with mild valvular
regurgitation⁎
–Myopia –Osteochondrosis Striae 196 Exon 4, c.6516GNC, p.Ala157Pro, Missense novel
Exon 8, c.9208GNA, p.Gly307Ser, Missense
IVS13, c.1467+32ANG Novel
MTR c.2756ANG (AG)
MTHFR c.677CNT (CT)
–Pectus
escavatum
–Kyphoscoliosis–Tricuspid valve
prolapse§
–Iridodonesis
–Mild elbow
valgus
–Moderate pulmonary
valve regurgitation
–Arachnodactyly
–ArmspanNHeight
3 14/36 M/44 DVT 3
superficial
venous
thrombosis
–Mitral valve prolapse
with mild valvular
regurgitation⁎
No
involvement
–Pectus escavatum Striae 222 Exon 8, c.9122TNC, p.Ile278Thr, Missense
Exon 12, c.1286_1288delTCA, p.Ile429del, Splice
IVS3, c.451+30ANG Novel
Exon 6, c.6955CNT (0.65/0.35), p.Tyr233Tyr, SNP
Exon 10, c.11686CNT (0.55/0.45) SNP
IVS12, c.1358-30CNT (0.76/0.24) SNP
IVS13, c.1467+32ANG Novel
MTHFR c.677CNT (TT)
–Arachnodactyly
4 15/24 M/30 DVT With
pulmonary
embolism
–Mitral valve prolapse
with mild regurgitation⁎
–Myopia –Pectus escavatum Striae 229 Exon 1, c.146CNT, p.Pro49Leu, Missense
IVS12, c.1357+1GNA Missense, Exon12 skipping
IVS13, c.1467+32ANG Novel
IVS13, c.1467+38ANG Novel
MTHFR c.1298ANG (AG)
–Mild
kyphoscoliosis
–Arachnodactyly
–Tricuspid valve prolapse
with mild regurgitation§
–Iridodonesis
–Flatfoot–mild pulmonary valve
regurgitation –ArmspanNHeight
5 4/22 F/27 No
involvement
–Mild mitral valve
prolapse⁎
–Myopia –Pectus carenatum Striae
Varicose vein
342 Exon 3, c.5873GNA, p.Arg125Gln, Missense
Exon 8, c.9122TNC, p.Ile278Thr, Missense
MTR c.2756ANG (AG)
–Ectopia lentis
DVT: deep vein thrombosis; SNP: single-nucleotide polymorphism; IVS: intron variable sequence; ⁎=[18]; §=[19].
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based on the association of connective tissue alterations with
a group of missense mutations located in the CBS C-terminal
region and affecting the domain interacting with S-adeno-
sylmethionine (AdoMet), so an increase of AdoMet cannot
further stimulate CBS production. Our 2 patients with a
mutation in CBS regulatory domain, carried mild cardiovas-
cular, skeletal and cutaneous stigmas, confirming the
MacLean's hypothesis [15]. Overall, the presence of a mild
connective tissue involvement, including heart valve altera-
tions and striae distensae in all 5 patients, suggests that the
connective tissue pathology in homocystinuria is relevant in
relation to the cardiovascular manifestations which may
become more severe with aging. Recently Hubmacher et al.
[16] demonstrated that high Hcy levels in homocystinuric
patients can modify fibrillin-1 via disulfide bonds by ren-
dering protein domains significantly more susceptible to
proteolytic degradation. This impairment could cause the
clinical manifestations, overlapping with MFS, present in
these patients. These results support our hypothesis on the
pathological molecular mechanism underlying the asso-
ciation between c.677CNT homozygous MTHFR poly-
morphism, mild homocysteinemia and more severe aortic
manifestations in Marfan syndrome [17] thus strengthening
the link between increased Hcy and damage to connective
tissue proteins rich in cysteines, as fibrillin 1.
Our data emphasizes the importance of extending the
clinical investigation for connective tissue manifestations
present in Marfan syndrome to homocystinuric patients.
Moreover, the detection of cardiovascular manifestations
suggests long term follow-ups for each patient.
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